EGI
CLDX icon

EAM Global Investors’s Celldex Therapeutics CLDX Stock Holding History

EAM Global Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-63,143
Closed -$2.27M – 90
2023
Q1 		$2.27M Sell
63,143
-8,911
-12% -$385K 0.64% 80
2022
Q4 		$3.21M Buy
+72,054
New +$2.57M 0.83% 27
2021
Q4 		– Sell
-96,528
Closed -$5.21M – 204
2021
Q3 		$5.21M Buy
96,528
+25,290
+36% +$1.19M 1.23% 6
2021
Q2 		$2.38M Buy
+71,238
New +$1.96M 0.66% 63
2021
Q1 		– Sell
-69,557
Closed -$1.22M – 149
2020
Q4 		$1.22M Sell
69,557
-29,193
-30% -$525K 0.33% 126
2020
Q3 		$1.46M Buy
+98,750
New +$1.16M 0.54% 95

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

EAM Global Investors's CLDX Position: Q2 2023 in Review

EAM Global Investors sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 63,143 shares — an estimated $2.27M sold.

EAM Global Investors first reported a position in CLDX in Q3 2020 and held it in 6 quarters. The position peaked at $5.21M in Q3 2021. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • EAM Global Investors reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EAM Global Investors sold 63,143 Celldex Therapeutics shares in Q2 2023, an estimated $2.27M.
  • EAM Global Investors first reported a position in Celldex Therapeutics in Q3 2020 and held it in 6 quarters.
  • EAM Global Investors's Celldex Therapeutics position peaked at $5.21M in Q3 2021.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on EAM Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.